Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial

PR Newswire

PRINCETON, N.J., Jan. 21, 2019 /PRNewswire/ -- Slayback Pharma LLC announced today that it has launched its first commercial product Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml.  This is the first and only ANDA approved by the FDA for Hydroxyprogesterone Caproate Injection in a multi-dose vial that is therapeutically equivalent to Makena.  

(PRNewsfoto/Slayback Pharma LLC)

Hydroxyprogesterone Caproate Injection, USP is available in a 250 mg/ ml, 5 ml multi-dose vial and can be ordered through your wholesaler/distributor.  Please contact our customer service team at 1-844-566-2505.

See the following important safety information and refer to the Package Insert for full prescribing information.

Indication

Hydroxyprogesterone caproate (HPC) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.  The effectiveness of HPC is based on improvement in the proportion of women who delivered <37 weeks of gestation.  There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of HPC has been demonstrated only in women with a prior spontaneous singleton preterm birth.  It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important Safety Information for Hydroxyprogesterone Caproate Injection (HPC)

HPC should not be used in women who have or have had any of the following conditions:

  • blood clots or blood clotting problems,
  • breast cancer, suspected breast cancer or other hormone-sensitive cancers, or history of these conditions;
  • unusual vaginal bleeding not related to your current pregnancy,
  • yellowing of the skin due to liver problems during pregnancy,
  • liver problems, including liver tumors,
  • uncontrolled high blood pressure.

Before you take HPC, tell your healthcare provider about all your medical conditions, including if you have:

  • an allergy to HPC, castor oil, or any of the other ingredients in HPC;
  • diabetes or prediabetes,
  • problems retaining water such as epilepsy, migraine headaches, asthma, heart or kidney problems,
  • depression,
  • yellowing of the skin or whites of your eyes,
  • or high blood pressure.

If any of these medical conditions occur while you are taking HPC, check with your doctor to see if you should continue using it.

Possible side effects: In a clinical study, some complications or new medical conditions associated with pregnancy occurred more often in women who received HPC.  These included miscarriage (pregnancy loss), stillbirth (fetal death), hospital admission for preterm labor, preeclampsia (high blood pressure and too much protein in the urine), gestational hypertension (high blood pressure caused by pregnancy), gestational diabetes (diabetes occurring during pregnancy), and oligohydramnios (low amniotic fluid levels).

Two serious side effects were reported in study patients: one developed a pulmonary embolus (blood clot in her lung), and the other developed cellulitis (injection site infection of the skin).  HPC may also cause other serious side effects including blood clots, allergic reactions, depression, and yellowing of your skin and the whites of your eyes.

The most common side effects of HPC include hives, itching, nausea, and diarrhea, and injection site reactions (pain, swelling, itching, and development of a hard lump).

You may report an adverse event related to Hydroxyprogesterone Caproate made by Slayback Pharma by calling 1-844-566-2505 or emailing [email protected].  If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for Hydroxyprogesterone Caproate Injection (HPC).        

References:
Hydroxyprogesterone Caproate Injection prescribing information. Slayback Pharma, 11/2018.

Makena® is a registered trademark of AMAG Pharmaceuticals, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/slayback-pharma-announces-launch-of-hydroxyprogesterone-caproate-injection-usp-1-250-mg-5-ml-in-a-multi-dose-vial-the-first-generic-equivalent-of-makena-injection-1-250-mg-5-ml-multi-dose-vial-300781572.html

SOURCE Slayback Pharma LLC

Copyright CNW Group 2019

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).